Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856196 | 0.86 | MAPT (0.70) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL10367050 | 0.86 | ALDH1A1 (0.55) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL10365412 | 0.86 | MAPT (0.51) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL22829053 | 0.85 | RAB9A (0.60) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL2300568 | 0.85 | MAPT (0.76) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL10364568 | 0.84 | MAPT (0.49) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL2856953 | 0.84 | ALDH1A1 (0.53) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL2722465 | 0.84 | TRPC1 (0.64) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL27171677 | 0.83 | RAB9A (0.57) | MAPTSMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL30861247 | 0.83 | RAB9A (0.57) | MAPTSMN1; SMN2POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-12077507-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240109845-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-04 | — | — | US | disclosed |
| EP-3555077-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIV CALIFORNIA (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11136297-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136297-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200131135-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-30 | — | — | US | disclosed |
| US-20200131135-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-30 | — | — | US | disclosed |
| EP-3555077-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The Regents of The University of California (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112420-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-21 | — | — | WO | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131135-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HRAS, KRAS, NRAS | MAPT 4236/4885SMN1; SMN2 3273/4885POLB 2228/4885 |
| US-11136297-B2 | Compositions and methods for treating cancer | HRAS, KRAS, NRAS | MAPT 4236/4885SMN1; SMN2 3273/4885POLB 2228/4885 |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | MAPT 4760/4885SMN1; SMN2 1771/4885POLB 3979/4885 |
| US-20240109845-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HRAS, KRAS, NRAS | MAPT 4236/4885SMN1; SMN2 3273/4885POLB 2228/4885 |
| US-12077507-B2 | Compositions and methods for treating cancer | HRAS, KRAS, NRAS | MAPT 4236/4885SMN1; SMN2 3273/4885POLB 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.